Institution
University of Texas Health Science Center at Houston
Education•Houston, Texas, United States•
About: University of Texas Health Science Center at Houston is a education organization based out in Houston, Texas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 27309 authors who have published 42520 publications receiving 2151596 citations. The organization is also known as: UTHealth & The UT Health Science Center at Houston.
Topics: Population, Poison control, Cancer, Stroke, Health care
Papers published on a yearly basis
Papers
More filters
National Institutes of Health1, Erasmus University Rotterdam2, Boston University3, University of Washington4, University of North Carolina at Chapel Hill5, Ghent University6, Columbia University7, University of South Florida8, Group Health Cooperative9, Cedars-Sinai Medical Center10, Johns Hopkins University11, University of Texas Health Science Center at Houston12, University of Arizona13
TL;DR: This meta-analysis included 20,890 participants of European ancestry from four CHARGE Consortium studies: Atherosclerosis Risk in Communities, Cardiovascular Health Study, Framingham Heart Study and Rotterdam Study, and identified eight loci associated with FEV1/FVC and one locus at or near genome-wide significance in theCHARGE Consortium dataset.
Abstract: Spirometric measures of lung function are heritable traits that reflect respiratory health and predict morbidity and mortality. We meta-analyzed genome-wide association studies for two clinically important lung-function measures: forced expiratory volume in the first second (FEV(1)) and its ratio to forced vital capacity (FEV(1)/FVC), an indicator of airflow obstruction. This meta-analysis included 20,890 participants of European ancestry from four CHARGE Consortium studies: Atherosclerosis Risk in Communities, Cardiovascular Health Study, Framingham Heart Study and Rotterdam Study. We identified eight loci associated with FEV(1)/FVC (HHIP, GPR126, ADAM19, AGER-PPT2, FAM13A, PTCH1, PID1 and HTR4) and one locus associated with FEV(1) (INTS12-GSTCD-NPNT) at or near genome-wide significance (P < 5 x 10(-8)) in the CHARGE Consortium dataset. Our findings may offer insights into pulmonary function and pathogenesis of chronic lung disease.
594 citations
TL;DR: Using an evidence-based approach to identify and recommend effective interventions directed at specific public health goals may reduce errors in how information is collected and interpreted, identify important gaps in current knowledge thus guiding further research, and enhance the Guide users' ability to assess whether recommendations are valid and prudent from their own perspectives.
593 citations
TL;DR: In this trial involving patients with advanced heart failure who were ineligible for heart transplantation, a small, intrapericardial, centrifugal‐flow LVAD was found to be noninferior to an axial‐ flow LVAD with respect to survival free from disabling stroke or device removal for malfunction or failure.
Abstract: BackgroundMechanical circulatory support with a left ventricular assist device (LVAD) is an established treatment for patients with advanced heart failure. We compared a newer LVAD design (a small intrapericardial centrifugal-flow device) against existing technology (a commercially available axial-flow device) in patients with advanced heart failure who were ineligible for heart transplantation. MethodsWe conducted a multicenter randomized trial involving 446 patients who were assigned, in a 2:1 ratio, to the study (centrifugal-flow) device or the control (axial-flow) device. Adults who met contemporary criteria for LVAD implantation for permanent use were eligible to participate in the trial. The primary end point was survival at 2 years free from disabling stroke or device removal for malfunction or failure. The trial was powered to show noninferiority with a margin of 15 percentage points. ResultsThe intention-to treat-population included 297 participants assigned to the study device and 148 participan...
592 citations
Emory University1, RTI International2, University of Iowa3, Case Western Reserve University4, University of Alabama at Birmingham5, Wayne State University6, Brown University7, Ohio State University8, Lucile Packard Children's Hospital9, Stanford University10, University of Texas Southwestern Medical Center11, Cincinnati Children's Hospital Medical Center12, Indiana University13, University of Texas Health Science Center at Houston14, Duke University15, University of New Mexico16, University of Rochester17, University of Pennsylvania18, Children's Mercy Hospital19, University of California, Los Angeles20, National Institutes of Health21
TL;DR: There have been considerable changes in care for mothers in preterm labor and for extremely preterm infants since the 1990s, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network has monitored changes.
Abstract: Obstet Gynecol Surv 2016;71(1):7–9Since the 1990s, there have been considerable changes in care for mothers in preterm labor and for extremely preterm infants. The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network has monitored changes in this
591 citations
Stanford University1, University of North Carolina at Chapel Hill2, Fred Hutchinson Cancer Research Center3, Vanderbilt University4, Anschutz Medical Campus5, University of Southern California6, Icahn School of Medicine at Mount Sinai7, University of California, San Francisco8, University of Hawaii9, University of Washington10, University of Texas Health Science Center at Houston11, University of Potsdam12, Johns Hopkins University13, Pennsylvania State University14, National Institutes of Health15, University of California, Davis16, Ohio State University17, Cancer Prevention Institute of California18, University of Vermont19, Rutgers University20
TL;DR: The value of diverse, multi-ethnic participants in large-scale genomic studies is demonstrated and evidence of effect-size heterogeneity across ancestries for published GWAS associations, substantial benefits for fine-mapping using diverse cohorts and insights into clinical implications are shown.
Abstract: Genome-wide association studies (GWAS) have laid the foundation for investigations into the biology of complex traits, drug development and clinical guidelines. However, the majority of discovery efforts are based on data from populations of European ancestry1-3. In light of the differential genetic architecture that is known to exist between populations, bias in representation can exacerbate existing disease and healthcare disparities. Critical variants may be missed if they have a low frequency or are completely absent in European populations, especially as the field shifts its attention towards rare variants, which are more likely to be population-specific4-10. Additionally, effect sizes and their derived risk prediction scores derived in one population may not accurately extrapolate to other populations11,12. Here we demonstrate the value of diverse, multi-ethnic participants in large-scale genomic studies. The Population Architecture using Genomics and Epidemiology (PAGE) study conducted a GWAS of 26 clinical and behavioural phenotypes in 49,839 non-European individuals. Using strategies tailored for analysis of multi-ethnic and admixed populations, we describe a framework for analysing diverse populations, identify 27 novel loci and 38 secondary signals at known loci, as well as replicate 1,444 GWAS catalogue associations across these traits. Our data show evidence of effect-size heterogeneity across ancestries for published GWAS associations, substantial benefits for fine-mapping using diverse cohorts and insights into clinical implications. In the United States-where minority populations have a disproportionately higher burden of chronic conditions13-the lack of representation of diverse populations in genetic research will result in inequitable access to precision medicine for those with the highest burden of disease. We strongly advocate for continued, large genome-wide efforts in diverse populations to maximize genetic discovery and reduce health disparities.
591 citations
Authors
Showing all 27450 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Paul M. Ridker | 233 | 1242 | 245097 |
| Eugene Braunwald | 230 | 1711 | 264576 |
| Eric N. Olson | 206 | 814 | 144586 |
| Hagop M. Kantarjian | 204 | 3708 | 210208 |
| André G. Uitterlinden | 199 | 1229 | 156747 |
| Gordon B. Mills | 187 | 1273 | 186451 |
| Eric Boerwinkle | 183 | 1321 | 170971 |
| Bruce M. Psaty | 181 | 1205 | 138244 |
| Aaron R. Folsom | 181 | 1118 | 134044 |
| Daniel R. Weinberger | 177 | 879 | 128450 |
| Bharat B. Aggarwal | 175 | 706 | 116213 |
| Richard A. Gibbs | 172 | 889 | 249708 |
| Russel J. Reiter | 169 | 1646 | 121010 |
| James F. Sallis | 169 | 825 | 144836 |
| Steven N. Blair | 165 | 879 | 132929 |